Tag: GlobeNewswire

The Phase 1/2 ABILITY-1 Clinical Trial is evaluating MDNA11 in expansion cohorts comprised of patients with advanced and metastatic gastrointestinal, endometrial, and melanoma cancers

Selected as one of the Top 150 Abstracts at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting

TORONTO and HOUSTON, Oct. 05, 2026 (GLOBE NEWSWIRE) — Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company developing Superkines for targeting cancer and autoimmune disease, today announced that an abstract reporting topline data from the Phase 1/2 study of MDNA11 has been selected for oral presentation at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting.

Details of the oral presentation are as follows:
Abstract Number: 517
Presentation Type: Oral Presentation
Presentation Date: Saturday, November 7, 2026
Presentation Time: 4:30-4:45 p.m. MST
Session: Oral Session 3, 3:30-4:50 p.m. MST
Location: Phoenix Convention Center, Room 301D, Phoenix, Arizona

Title: “MDNA11 Demonstrates Clinical Activity as Monotherapy and in Combination with Pembrolizumab in Biomarker-Enriched Gastrointestinal Malignancies, Including ICI-Refractory Disease.”

About Medicenna Therapeutics
Medicenna is a clinical-stage immunotherapy company developing engineered cytokine therapies designed to selectively engage the immune system to treat cancer. The Company’s most advanced program, bizaxofusp (formerly MDNA55), is a targeted IL-4 Empowered Superkine that has been evaluated in more than 130 patients across five clinical trials, including a Phase 2b study in recurrent glioblastoma. Bizaxofusp has received Fast Track designation from the FDA and Orphan Drug designation in the United States and Europe. Medicenna is also advancing MDNA11, a long-acting IL-2 Superkine designed to selectively activate cancer-fighting immune cells, which is currently being evaluated in the Phase 1/2 ABILITY-1 study and the Phase 1b NEO-CYT study. The Company is also developing MDNA113, a targeted PD-1 x IL-2 bifunctional immunotherapy for solid tumors, and MDNA209, an antagonist of CD122 blocking IL-2/IL-15 signaling, using its proprietary BiSKIT and T-MASK platforms.

For more information, please visit www.medicenna.com, and follow us on X and LinkedIn.

Forward-Looking Statements
This news release contains forward-looking statements within the meaning of applicable securities laws. Forward-looking statements include, but are not limited to, express or implied statements regarding the future operations of the Company, estimates, plans, strategic ambitions, partnership activities and opportunities, objectives, expectations, opinions, forecasts, projections, guidance, outlook or other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expect”, “believe”, “seek”, “potentially” and similar expressions. and are subject to risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations include the risks detailed in the latest annual information form of the Company and in other filings made by the Company with the applicable securities regulators from time to time in Canada.

The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date hereof and except as required by law, we do not intend and do not assume any obligation to update or revise publicly any of the included forward-looking statements.

This news release contains hyperlinks to information that is not deemed to be incorporated by reference in this new release.

Investor and Company Contact
Daniel Scarr
Director, Corporate Development
Medicenna Therapeutics
ir@medicenna.com 

CALGARY, Alberta, Oct. 05, 2026 (GLOBE NEWSWIRE) — Canoe Financial is proud to announce a new sponsorship partnership with Canadian Olympic Gold Medallist and World Champion canoeist Katie Vincent, one of Canada’s most accomplished athletes and a leading figure in the sport of canoe sprint. The partnership will extend through the 2028 Olympic cycle and will feature a national marketing campaign built around the principles that define both Vincent’s athletic journey and Canoe Financial’s investment philosophy: Discipline compounds. Performance is earned.

As Canada’s premier canoe sprint athlete, Vincent has established herself among the world’s elite through years of dedication, preparation, and relentless commitment to excellence. Her career includes Olympic gold and bronze medals, world championship titles, and multiple world records, achievements built through a disciplined process long before race day.

The partnership reflects a natural alignment between Vincent’s approach to athletic performance and Canoe Financial’s approach to investing. Both recognize that success is rarely defined by a single moment. It is the result of a disciplined process, repeated consistently over time.

“Katie’s story is about more than winning medals,” said Darcy Hulston, President and Chief Executive Officer of Canoe Financial. “Her success is built on the same beliefs that guide our business every day. Driven by process. Discipline compounds. Performance is earned. Those beliefs are at the heart of everything we do for our investors, and Katie is an inspiring example of what can be achieved when you commit to them over the long term.”

The sponsorship also represents a uniquely authentic connection between Canoe Financial and the sport of canoeing. As Vincent competes on the world stage, Canoe Financial will support her journey while celebrating the values of perseverance, preparation, and excellence that resonate with Canadians from coast to coast.

About Canoe Financial
Canoe Financial is one of Canada’s fastest growing independent mutual fund companies managing nearly $25 billion in assets across a diversified range of award-winning investment solutions. Founded in 2008, Canoe Financial is an employee-owned investment management firm focused on building financial wealth for Canadians. Canoe Financial has a significant presence across Canada, including offices in Calgary, Toronto and Montreal.

Contact
Investor Relations
1–877–434–2796
info@canoefinancial.com

Commissions, trailing commissions, management fees and expenses all may be associated with mutual fund investments. Please read the prospectus before investing. Mutual funds are not guaranteed, their values change frequently and past performance may not be repeated.

Coop Pank AS (the Bank) announces that during the period 28.09.2026 – 04.10.2026, it has acquired the company’s own shares on the Nasdaq Tallinn Stock Exchange as follows:

Date	Aggregated volume (pcs)	Weighted average price per day (EUR)
28.09.2026	9,264	2.31000000
29.09.2026	9,264	2.30500000
30.09.2026	3,516	2.29000000
01.10.2026	2,742	2.30000000

Bank is acquiring its own shares based on the resolution of the company’s general meeting of shareholders held on 8 April 2026, and under the conditions decided by the Supervisory Board and Management Board. Summary data of the acquisitions will be disclosed no later than on the seventh trading day after the transaction and will be made available to the Financial Supervision and Resolution Authority, via the Nasdaq Tallinn system, and on Coop Bank´s investor website.

Additional information:
Paavo Truu
CFO
Phone: 5160 231
E-mail: paavo.truu@cooppank.ee

Coop Pank, based on Estonian capital, is one of the five universal banks operating in Estonia. The bank has 239,100 clients who use everyday banking services. Coop Pank uses the synergy created between retail trade and banking and brings everyday banking solutions closer to people. The majority shareholder of the Bank is a domestic retail chain Coop Eesti, the sales network of which comprises over 330 stores.

AS Tallinna Sadam (hereinafter Tallinna Sadam) and TT-Line GmbH (hereinafter TT-Line) have signed an agreement for the operation of a vessel on the Muuga (Estonia)–Vuosaari (Finland) route. The route will be served by a ro-pax ferry with around 2 000 freight lanemeters and a restaurant/café, a passenger lounge and other facilities for passengers and truckdrivers as well as cabins. The vessel used is intended to be announced in November. The vessel is expected to start operating on the route during the first quarter of 2027, with the exact launch date to be confirmed. 

The Muuga–Vuosaari ferry connection is of strategic importance for freight transport between Estonia and Finland. It provides logistics and transport companies with a fast maritime route and helps divert trucks and trailers away from the city centres of Tallinn and Helsinki. The connection supports the competitiveness of Estonia’s export-oriented economy by improving companies’ access to Finnish and, more broadly, Nordic markets. At the same time, it strengthens the position of Estonia and Muuga harbour as a key north-south transport and transit corridor, linking Finland to the Baltic states and, subsequently, to Central and Southern Europe.

The regular ferry route between the cargo harbours operated by the ports of Tallinn and Helsinki was launched in 2017 and has been served by both Tallink and Eckerö Line. Currently, the route is operated by Eckerö Line with the vessel Finbo Cargo.

“Freight volumes on the Muuga–Vuosaari route have grown steadily over the years and are now approaching the limits of what can be handled with a single vessel. This clearly demonstrates market demand for additional capacity and more frequent departures. The addition of a second operator will provide customers with greater choice and flexibility, strengthen the reliability of the connection and support further growth in trade between Estonia and Finland,” said Rene Pärt, Member of the Management Board of Tallinna Sadam.

The agreement will contribute to the port’s revenues through vessel call, cargo and passenger fees, while enabling more efficient use of existing infrastructure.

TT-Line is a family-owned shipping company established in 1962 in Germany.  Its fleet consists of 9 ro-pax vessels. The company’s core business is the transport of passengers, passenger vehicles and freight, connecting Germany,Sweden, Poland and Lithuania and serving routes that include the ports of Travemünde, Rostock, Trelleborg, Karlshamn, Świnoujście and Klaipėda.

Tallinna Sadam is one of the largest cargo- and passenger port complexes in the Baltic Sea region. In addition to passenger and freight services, Tallinna Sadam group also operates in shipping business via its subsidiaries – OÜ TS Laevad provides ferry services between the Estonian mainland and the largest islands, and OÜ TS Shipping charters its multifunctional vessel Botnica for icebreaking and offshore services in Estonia and projects abroad. Tallinna Sadam group is also a shareholder of an associate AS Green Marine, which provides waste management services.

Additional information:

Angelika Annus
Head of Investor Relations
Tel. +372 5649 6230
angelika.annus@ts.ee

WASHINGTON and NEW YORK, Oct. 05, 2026 (GLOBE NEWSWIRE) — The Carlyle Group Inc. (NASDAQ: CG) announced today that it will release financial results for the third quarter 2026 on Thursday, November 5, 2026, and host a conference call at 8:30 a.m. EST. The conference call will be available via public webcast from the Events & Presentations section of ir.carlyle.com and a replay will also be available after the call’s completion.

Chief Executive Officer Harvey Schwartz, Chief Financial Officer Justin Plouffe, and Head of Public Investor Relations Daniel Harris, will review the results during the call.

The earnings release will be available through all Carlyle channels, including the Earnings Releases section of ir.carlyle.com and the firm’s X and LinkedIn accounts.

About Carlyle

Carlyle (NASDAQ: CG) is a global investment firm with deep industry expertise that deploys private capital across three business segments: Global Private Equity, Global Credit, and Carlyle AlpInvest. With $485 billion of assets under management as of June 30, 2026, Carlyle’s purpose is to connect people, ideas, and capital to fuel growth for companies and performance for investors. Carlyle employs more than 2,500 people in 28 offices across four continents.

Contacts
Public Investor Relations
Daniel Harris
+1 (212) 813-4527
daniel.harris@carlyle.com

Media
Brittany Bensaull
+1 (212) 813-4839
brittany.bensaull@carlyle.com 

SAN DIEGO, Oct. 05, 2026 (GLOBE NEWSWIRE) — LPL Financial LLC announced today that Praxis Financial Partners advisors Scott Christian, CFP®, Cecil Loyd, CIMA®, Jay Gentry, CIMA® and Matt Dion have joined LPL Financial’s broker-dealer and Registered Investment Advisor (RIA) platform. The team reported serving approximately $1.1 billion in advisory, brokerage and retirement plan assets* and joins LPL from Wells Fargo Advisors Financial Network.

Based in Alpharetta, Ga., Praxis Financial Partners is a planning-focused wealth management practice serving business owners, corporate retirees, successful executives and multigenerational families across 24 states. The firm traces its roots to 2013, when Christian and Loyd launched Praxis after working together for decades. The name “Praxis,” derived from the Greek word for “process,” reflects the team’s planning-based philosophy. Gentry joined the practice in 2020 after 20 years in asset management distribution, while Dion joined in 2024 after 15 years as an advisor.

Today, the practice combines the experience of four advisors with a tenured support team that includes Jody Smith, Zac Hirschler, Ashlyn Presley, Ellen Rick, Seleena Harris and Parvathy Eashwaran. The team credits its service model as a key reason for its client retention, referral growth and longstanding multigenerational relationships.

“We’ve always believed that good financial advice begins with understanding what matters most to each client,” Christian said. “We take the time to learn their goals, priorities and risk tolerance, then develop customized strategies supported by an ongoing review process. Every client is different, and our objective is to create solutions tailored to their unique circumstances rather than relying on a one-size-fits-all approach.”

Collaboration is central to the firm’s client experience. The advisors regularly work together on client strategies and maintain weekly investment committee meetings, where portfolio decisions, market developments and investment opportunities are evaluated collectively. By managing a significant portion of client assets in-house, the team provides clients with direct access to the advisors responsible for investment decisions and portfolio construction.

“The foundation of our business is service,” Gentry said. “Many of our client relationships span multiple generations, and that continuity is made possible by an incredible team of professionals who care deeply about the people we serve. Our clients know they can count on the same familiar faces year after year, and that’s something we are incredibly proud of.”

Why Praxis Financial Partners Chose LPL

As the firm evaluated its next chapter, the advisors sought a partner that would provide greater flexibility, advanced planning capabilities and access to emerging technology.

“The financial advice landscape continues to evolve rapidly, and we wanted a partner that allows us to stay ahead of those changes,” Christian said. “LPL’s open architecture platform gives us the freedom to build the wealth management ecosystem we believe best serves our clients. The planning tools, flexibility and ability to create our own technology stack will help us continue delivering exceptional service while positioning the firm for future growth.”

Dion added, “We were looking for a partner committed to innovation and focused on helping advisors deliver greater value. LPL’s technology and resources will enable us to continue enhancing the client experience while maintaining the personalized service our clients expect.”

The team also valued LPL’s ability to support its long-term independence strategy. After evaluating more than a dozen firms, Praxis selected LPL because it offered the resources and scale the advisors were seeking while allowing them to maintain ownership of their business and preserve future succession and continuity options.

LPL Chief Growth Officer Marc Cohen said, “Scott, Cecil, Jay and Matt have built Praxis Financial Partners with a clear sense of purpose. Even the firm’s name speaks to their disciplined, planning-first approach, and that philosophy comes through in everything from their collaborative investment process to the multigenerational relationships they’ve cultivated over the years. They’ve created a business that balances deep technical expertise with a genuine commitment to understanding what matters most to each client. We are honored they chose LPL for this next chapter and look forward to supporting Praxis Financial Partners as they continue evolving their business while staying true to the values that have driven their success.”

Related

Advisors, learn how LPL Financial can help take your business to the next level.

About LPL Financial

LPL Financial Holdings Inc. (Nasdaq: LPLA) is among the fastest growing wealth management firms in the U.S. As a leader in the financial advisor-mediated marketplace, LPL supports more than 32,000 financial advisors and the wealth management practices of approximately 1,100 financial institutions, servicing and custodying approximately $2.6 trillion in brokerage and advisory assets on behalf of approximately 8 million Americans. The firm provides a wide range of advisor affiliation models, investment solutions, fintech tools and practice management services, ensuring that advisors and institutions have the flexibility to choose the business model, services, and technology resources they need to run thriving businesses. For further information about LPL, please visit www.lpl.com.

Securities and advisory services offered through LPL Financial LLC (“LPL Financial”), a registered investment advisor and broker-dealer, member FINRA/SIPC. Praxis Financial Partners and LPL Financial are separate entities.

Throughout this communication, the terms “financial advisors” and “advisors” are used to refer to registered representatives and/or investment advisor representatives affiliated with LPL Financial.

We routinely disclose information that may be important to shareholders in the “Investor Relations” or “Press Releases” section of our website.

*Value approximated based on asset and holding details provided to LPL from end of year, 2025.

Media Contact: 
Media.relations@LPLFinancial.com  

Tracking #1175084

LOS ANGELES, CA, Oct. 05, 2026 (GLOBE NEWSWIRE) — Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), a global leader in AL Amyloidosis, today announced that it will present at the 45th Annual J.P. Morgan Healthcare Conference being held January 11-14, 2027 in San Francisco, CA.

A link to access the replay, when available, will be posted to the Immix website on the Presentation & Events page under the Investors section.

About Immix Biopharma, Inc.
Immix Biopharma, Inc. (ImmixBio) (Nasdaq: IMMX) is a global leader in AL Amyloidosis. AL Amyloidosis is a devastating disease where the immune system, that’s supposed to protect, instead produces toxic light chains, clogging up the heart, kidney and liver, causing organ failure and death. Our lead candidate is sterically-optimized BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy NXC-201 with a proprietary CD3ζ, CD8 hinge and binder “digital filter” designed to filter out non-specific activation. NXC-201 teaches the immune system to recognize and eliminate the source of the toxic light chains. NXC-201 is being evaluated in the U.S. multi-center study for relapsed/refractory AL Amyloidosis NEXICART-2 (NCT06097832), with a potentially registrational design. NXC-201 has been awarded Breakthrough Therapy Designation (BTD) and Regenerative Medicine Advanced Therapy (RMAT) by the US FDA and Orphan Drug Designation (ODD) by FDA and in the EU by the EMA.

Contacts
Mike Moyer
LifeSci Advisors
mmoyer@lifesciadvisors.com 

Company Contact
irteam@immixbio.com 

Companies to Meet Formally with FDA’s Center for Veterinary Medicine on November 19th for Pre-Submission Conference; U.S. Manufacturing Strategy Underway to Support Potential 2027 Veterinary Product Launch

FORT LAUDERDALE, Fla., Oct. 05, 2026 (GLOBE NEWSWIRE) — Endovia Health Sciences, Inc. (“Endovia” or the “Company”) (NYSE American: EDVA), in association with Lupvindol BioSciences (“Lupvindol”), today announced that the U.S. Food and Drug Administration’s (“FDA”) Center for Veterinary Medicine has determined that the proposed use of CannEpil^®, an investigational cannabidiol (“CBD”) and tetrahydrocannabinol (“THC”) oral solution, for the control of pain associated with bone cancer in dogs qualifies as a “minor use” under the Minor Use and Minor Species (“MUMS”) program.

The FDA determination establishes CannEpil’s eligibility to pursue the conditional approval pathway for this proposed indication. The FDA further determined that the minor-use status will be maintained through approval of the applicable New Animal Drug Application (“NADA”).

Under the MUMS framework, qualifying new animal drugs may be eligible for conditional approval which is a regulatory pathway designed to facilitate earlier availability of therapies for uncommon diseases and conditions in animals. Conditional approval requires satisfaction of applicable FDA requirements, including safety and manufacturing standards and a reasonable expectation of effectiveness, while allowing additional effectiveness data required for full approval to be collected following conditional approval.

Endovia and Lupvindol are scheduled to meet formally with the FDA on November 19, 2026, for a Pre-Submission Conference to discuss and align with the FDA on the proposed CannEpil^® development program, including the studies, manufacturing requirements and regulatory submissions necessary to pursue conditional approval.

In parallel with the regulatory program, Endovia and Lupvindol are actively sourcing and finalizing U.S.-based manufacturing capabilities for CannEpil^®. This work is intended to establish a scalable, FDA-compliant domestic supply chain capable of supporting the clinical and regulatory program and, subject to receipt of the necessary regulatory approvals, a potential commercial launch for veterinary use in 2027.

“This determination represents an important regulatory milestone for CannEpil^® and provides greater clarity around the pathway we are pursuing with the FDA,” said Brady Cobb, Interim Chief Executive Officer of Endovia Health Sciences. “Importantly, we are not waiting to begin preparing for commercialization. Alongside Lupvindol, we are advancing our FDA development program while simultaneously working to establish U.S. manufacturing and supply capabilities that can support a potential veterinary launch in 2027, subject to regulatory approval.”

Cobb continued, “We believe CannEpil has the potential to demonstrate what a science-driven, federally regulated cannabinoid medicine can look like in the United States. Our veterinary program gives us an opportunity to address a serious unmet need for dogs suffering from cancer-related pain while building the regulatory, manufacturing and scientific infrastructure that we believe can support the broader development of CannEpil.”

The MUMS conditional approval pathway was established to encourage development of new animal drugs for uncommon conditions affecting relatively small populations. Following conditional approval, a sponsor may legally market a qualifying animal drug while continuing to collect the additional effectiveness data necessary to support full FDA approval, subject to applicable statutory and regulatory requirements and annual FDA renewal.

CannEpil^® remains an investigational new animal drug and has not been approved or conditionally approved by the FDA. The Company’s anticipated development timelines, including a potential 2027 commercial launch, remain subject to FDA review, successful completion of applicable regulatory requirements, manufacturing readiness and other factors.

About CannEpil^®

CannEpil^® is a proprietary cannabinoid-based oral formulation containing cannabidiol (CBD) and tetrahydrocannabinol (THC). Endovia and Lupvindol BioSciences are advancing CannEpil through the FDA’s Center for Veterinary Medicine for the proposed control of pain associated with bone cancer in dogs.

The veterinary development program is part of Endovia’s broader strategy to develop cannabinoid-based therapeutics through established federal regulatory pathways and to build a platform capable of supporting additional veterinary and human therapeutic applications, subject to applicable statutory and regulatory requirements.

About Endovia Health Sciences

Endovia Health Sciences, Inc. (NYSE American: EDVA) is a cannabinoid health sciences company focused on building a diversified platform across pharmaceutical development, FDA-regulated human and veterinary therapeutics, international pharmaceutical commercialization and cannabinoid-based wellness products.

About Lupvindol Biosciences Ltd.

Lupvindol Biosciences Ltd. is a pharmaceutical and bioscience development company with expertise in cannabinoid-based therapeutics and U.S. FDA regulatory pathways. The company is led by Hunter Land, Ph.D., whose experience includes participation in the development of Epidiolex^® and Sativex^® at GW Pharmaceuticals.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform act of 1995 including statements regarding the development and commercialization of CannEpil^®; obtaining a manufacturing source, and a potential commercial veterinary launch in 2027.

Forward-looking statements are based on current expectations, estimates, projections and assumptions and involve risks and uncertainties that could cause actual results to differ materially. Some or all of these risks may not occur. These risks include the Company’s ability to obtain additional financing; the development of and obtaining regulatory authorization for and commercialize CannEpil^® for veterinary use, the results of any clinical trials, the availability of raw materials, the ability to obtain a manufacturer to meet our needs on a financially viable basis, ; maintaining its rights under applicable license agreements; the enactment, implementation or impact of proposed legislation or regulatory initiatives; ability to meet competition from both CBD and conventional pharmaceuticals products ,our ability to successfully execute commercialization or strategic-partnering arrangements, and the risk that that the market or demand for any resulting product we seek to commercialize in the future could be less than expected or projected.

Additional risks are described in the Company’s filings with the Securities and Exchange Commission, including the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, and the final prospectus filed pursuant to Rule 424(b)(3) on August 28, 2026.

Forward-looking statements speak only as of the date of this press release, and the Company undertakes no obligation to update or revise any such statements whether as a result of new information, future events or otherwise, except as required by applicable law.

Investor Contact
Endovia Health Sciences
investors@endoviasciences.com

Media Contact
Angela Gorman
AMWPR
angela@amwpr.com
917-348-0083

Second tranche completes the strategic relationship announced on June 16, 2026, adding exposure to anorthosite — an aluminum-rich rock characteristic of the lunar highlands — for sustainable alumina, refractory systems, lunar regolith simulants and research into 3D-printed lunar construction materials

CHARLOTTE, N.C., Oct. 05, 2026 (GLOBE NEWSWIRE) — via IBN — Greenland Mines Ltd (“Greenland Mines” or the “Company”) (Nasdaq: GRML; FSE: HK6), a Greenland-focused critical-minerals development company, today announced that it has exercised in full its option to acquire an additional 9.9% of Anortech.

When Greenland Mines made its initial investment in June, the Company described AnorTech as a differentiated critical-materials and processing platform: sustainable smelter-grade alumina, high-purity alumina, CO2-free cement, and related industrial materials from AnorTech’s 100%-owned Gronne Bjerg anorthosite project, approximately 80 kilometers from the capital of Nuuk on open tidewater. Greenland Mines sees Gronne Bjerg as a potential source of feedstock for U.S. smelter-grade and high-purity alumina production in a market where net imports met an estimated 71% of U.S. alumina consumption in 2025, according to the U.S. Geological Survey. Today’s exercise reflects a second, and increasingly important, dimension of that platform — anorthosite’s potential role in lunar construction research.

Anorthosite — a rock composed predominantly of plagioclase feldspar — is a major component of the lunar highlands. Terrestrial anorthosite can serve as an analogue for aspects of lunar highlands geology and as a component of lunar regolith simulants. AnorTech reports that it has supplied its anorthosite to space-sector researchers for use as a lunar simulant.

AnorTech reports that its natural anorthosite shares compositional and mineralogical characteristics with lunar highlands materials, supporting the development and testing of technologies on Earth. Over more than a decade, it has advanced anorthosite-based lunar regolith simulants, 3D-printable concrete and construction materials, refractory concretes and cements, and both smelter-grade and high-purity alumina production. Its work includes research into potential lunar construction applications; deployment would require further testing under lunar conditions.

Greenland Mines’ strategy is to build a critical-materials platform spanning advantaged upstream assets in Greenland and U.S. refining and manufacturing opportunities, supported by partnerships in allied jurisdictions — the Company’s North Atlantic Critical Metals Corridor. AnorTech extends that platform in two directions:

Exposure to proprietary, patent-pending processes to produce sustainable smelter-grade and high-purity alumina from anorthosite without bauxite-residue tailings, generating saleable amorphous-silica and calcium silicate by-products, together with CO2-free refractory cement, 3D-printable cement and alumina-based catalysts. AnorTech has shipped 15 tons of Gronne Bjerg anorthosite to Ontario in preparation for pilot-plant testing. AnorTech reports that its alumina flowsheet has been demonstrated at laboratory scale, with a planned pilot program intended to produce smelter-grade and high-purity alumina samples for engineering tests and customer evaluation.

Potential dual-use applications — including simulants, printable construction materials, refractories and resource-processing technologies — relevant to research on using the Moon’s own materials for construction and reducing the amount of material that must be transported from Earth.

The characteristics that make Gronne Bjerg attractive as a terrestrial industrial-minerals project — a massive and homogeneous anorthosite body averaging 32% aluminum oxide, on deep-water tidewater approximately 80 kilometers from Nuuk and its international airport, adjacent to significant hydroelectric potential — could also support the supply of lunar-analogue material for research and testing on Earth. Greenland Mines sees the project’s tidewater location as a potential link between feedstock from a friendly North Atlantic jurisdiction and future U.S. alumina refining, helping bring more processing and manufacturing value into the United States. Greenland Mines believes the combination of AnorTech’s materials science and Greenland’s resource base positions the group to participate in space-materials research, defence, advanced-manufacturing and supply-chain-security themes that are increasingly central to allied industrial policy.

Bo Møller Stensgaard, President of Greenland Mines, commented:

“Rebuilding America’s aluminum and advanced-materials industries requires secure feedstock and more refining capacity on U.S. soil. We see the opportunity to connect Greenland resources with U.S. production of smelter-grade alumina for American aluminum smelters and high-purity alumina for semiconductor and other advanced-materials supply chains. The objective is a supply chain from Greenland to the United States that can operate independently of Chinese refining, with more processing, manufacturing and value creation in America. That is how feedstock from friendly shores could support greater U.S. industrial self-sufficiency.

“Alongside that U.S. industrial opportunity, AnorTech’s simulants and materials development support research on lunar surface infrastructure and the use of local resources for construction. Doubling our position gives Greenland Mines shareholders exposure to this U.S. industrial strategy, alongside longer-term potential in lunar applications.”

Jim Cambon, President of AnorTech, commented:

“Greenland Mines’ decision to exercise its option in full is a strong endorsement of what we are building at AnorTech. Greenland Mines understands the value we are creating from Greenland anorthosite and its exciting future as a key component in the aluminum critical mineral supply chain and as a material for research into future lunar construction. We are moving our smelter grade alumina and high purity alumina technologies towards commercialization while continuing our successful test programs on 3D-printable and refractory cements, which may also inform future lunar construction applications. We are working with a number of groups in the space industry who are using our anorthosite as a lunar simulant and we expect this sector to grow as lunar programs ramp up.  We look forward to maximizing the synergies between our companies and working with Greenland Mines as a strategic shareholder as we advance our lunar materials, smelter grade alumina and high purity alumina programs.”

Transaction Terms

The option to acquire an additional 9.9% of AnorTech was granted under the share exchange agreement between the Company and AnorTech dated June 15, 2026, announced on June 16, 2026, and completed on June 22, 2026, through which Greenland Mines acquired its initial 19,958,503 AnorTech shares. On completion of the exercise, Greenland Mines will hold 45,127,172 AnorTech shares.

Under the option granted to Greenland Mines pursuant to the share exchange agreement dated June 15, 2026 (the “Option”), the Company has exercised the Option in full to acquire 25,168,669 AnorTech common shares (the “Option Shares”) at a deemed price of C$0.30 per Option Share, for aggregate consideration of approximately US$5,298,000 (C$7,550,000). The consideration is satisfied through the issuance by Greenland Mines to AnorTech of common shares of Greenland Mines, with the exact number of shares based on the 10-day volume-weighted average trading price of the Greenland Mines common shares on Nasdaq at the time of closing.

Following the issuance of the Option Shares, Greenland Mines will own 45,127,172 AnorTech common shares, representing 19.9% of AnorTech’s issued and outstanding share capital. The Option Shares are subject to a contractual lock-up of 60 months from issuance, consistent with the initial tranche, in addition to a four-month Canadian statutory hold period. One-half of the Greenland Mines shares issued to AnorTech are subject to a 12-month contractual lock-up and the remaining one-half to a 24-month contractual lock-up. AnorTech currently owns 318,000 shares of Greenland Mines from previous transactions. The Greenland Mines shares will be issued in a private transaction exempt from the registration requirements of the U.S. Securities Act of 1933, as amended. Completion of the exercise is subject to acceptance by the TSX Venture Exchange and customary closing conditions.

About Greenland Mines Ltd

Greenland Mines Ltd is a Nasdaq-listed resource development and mining company focused on the development of the Skaergaard Project in southeast Greenland and the Sarfartoq neodymium-praseodymium rare earths project in southwest Greenland. The Company’s strategy is centered on building a multi-asset platform with exposure to rare earth magnet materials, precious metals and select midstream processing opportunities, while advancing its assets and broader North Atlantic Critical Metals Corridor vision linking Greenland resources with allied downstream jurisdictions and industrial infrastructure.

About AnorTech Inc.

AnorTech (formerly Hudson Resources Inc.) is pioneering the next generation of sustainable materials from anorthosite with over 12 years experience in developing anorthosite products and 25 years experience exploring, building and operating projects in Greenland. The Company owns 100% of the Gronne Bjerg anorthosite project in Greenland — strategically located approximately 80 km from Nuuk, the capital of Greenland, on open tidewater and adjacent to significant hydroelectric potential. AnorTech is advancing multiple product lines towards commercialization, including zero-waste smelter grade alumina (SGA) and high purity alumina (HPA); next generation alumina-based catalysts for CO2 capture; CO2-free refractory cement and advanced 3D-printable cement; and research into lunar construction materials using anorthosite-based concrete. Its high-purity alumina development work could support a domestic U.S. supply of advanced materials, including synthetic sapphire for semiconductor applications, by combining Greenland feedstock with potential U.S. refining and manufacturing. AnorTech filed a U.S. provisional patent in 2025 to protect its proprietary sustainable SGA and HPA process and has shipped 15 tons of Gronne Bjerg anorthosite to Ontario in preparation for pilot plant testing. AnorTech has over C$3 million in working capital.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are often identified by words such as “believe,” “expect,” “anticipate,” “intend,” “plan,” “potential,” “could,” “may,” “will,” “should,” “estimate,” “objective” and similar expressions. These forward-looking statements include statements regarding the completion of the exercise of the Option and the issuance of the Option Shares and the Greenland Mines shares, the receipt of TSX Venture Exchange acceptance, the strategic benefits of the Company’s investment in AnorTech, AnorTech’s proposed Anorthosite Lunar Materials Innovation Program and any partnership, funding or agreement in respect of it, the suitability of Gronne Bjerg anorthosite as a lunar regolith simulant or as feedstock for lunar construction materials, refractory systems or alumina, the future commercialization of AnorTech’s technologies, future pilot plant activities, future demand from space, defence and advanced-manufacturing markets, the development of a North Atlantic Critical Metals Corridor and the Company’s broader strategy.

These statements are based on current expectations, assumptions and available information and are subject to a range of risks and uncertainties, including regulatory and exchange approvals, technical and commercialization risk, pilot scale-up risk, the risk that no agreement in respect of AnorTech’s proposed lunar materials program is concluded with any space agency or commercial space company, the timing and scope of governmental and commercial lunar programs, market conditions, financing availability, industrial partner engagement, logistics constraints and project execution risk, as well as the exploration, resource-estimation, metallurgical, engineering, environmental, social, permitting, infrastructure, commodity-price, counterparty and other risks described in documents filed or to be filed with the U.S. Securities and Exchange Commission, any of which could cause actual results to differ materially from those expressed or implied. Statements in this press release regarding AnorTech, its technologies, its Gronne Bjerg project and its proposed lunar materials program are based on information provided by or publicly disclosed by AnorTech, which Greenland Mines has not independently verified. Greenland Mines holds a minority interest in, and does not control, AnorTech. No assurance can be given that studies, partnerships, transactions, development decisions or production will occur on the timing contemplated or at all.

Readers should carefully consider these factors and the other risks and uncertainties described in the Company’s SEC filings. All information in this press release is provided as of its date, and the Company undertakes no obligation to update any forward-looking statement except as required by applicable law.

Investor Contact and Corporate Communications:

ir@greenlandmines.com
Website: www.greenlandmines.com

Corporate Communications:
IBN.Ai
Austin, Texas
www.IBN.Ai
512.354.7000 Office
Editor@IBN.Ai

Five-year ordering period through September 2031 positions Cyabra to compete to supply AI-powered image and video analysis that uncovers manipulated, synthetic, and inauthentic content

New York, NY, Oct. 05, 2026 (GLOBE NEWSWIRE) —  Cyabra, Inc. (Nasdaq: CYAB) (“Cyabra” or the “Company”), an artificial intelligence (“AI”)-powered narrative intelligence company that helps governments and enterprises detect coordinated manipulation and protect digital trust, today announced that its wholly owned subsidiary, Cyabra Strategy Inc., has been awarded positions under both the Image Information and Video Information categories of the Federal Bureau of Investigation’s (FBI) Specialized Open-Source Intelligence (OSINT) Tools multi-award Indefinite Delivery, Indefinite Quantity (IDIQ) contract.

The five-year ordering period runs through September 2031, during which Cyabra is eligible to compete for task orders from FBI headquarters divisions and field offices across the United States.

As generative AI tools make deepfake videos, altered imagery, and synthetic visual content faster, cheaper, and harder to detect manually, federal law enforcement and intelligence agencies increasingly need scalable, evidence-based analysis. Cyabra’s narrative intelligence platform, delivered as cloud-native SaaS, equips analysts with authenticity scoring and supporting forensic signals for images and video. Capabilities include detection of GAN- and diffusion-generated content, face swaps and splice points, plus C2PA content-provenance checks and account authenticity scoring for context on who is sharing the content.

“When an image or video surfaces in an investigation, the first question is whether it is real, and the next is whether the account sharing it is authentic,” said Dan Brahmy, Co-Founder and CEO of Cyabra. “The FBI’s decision to create dedicated image and video categories signals that investigative demand is moving toward evidence-based answers that hold up under scrutiny. Selection in both positions Cyabra to compete for that demand, and we are committed to building our U.S. public sector business, where we see significant opportunity.”

“Our selection for this FBI contract vehicle reflects the strength of Cyabra’s visual AI analysis capabilities,” said Keith E. Noble, Ph.D., Vice President of U.S. Government Sales at Cyabra. “This IDIQ gives FBI divisions a streamlined way to acquire image and video analysis in support of their investigative missions, and we look forward to competing to provide ours.”

Selection for the FBI’s Specialized OSINT Tools IDIQ vehicle is an important step in Cyabra’s federal expansion strategy. It builds on Cyabra’s existing public-sector contract vehicles and channel partnerships serving U.S. federal, defense, and intelligence agencies. Cyabra believes the award establishes a pathway to recurring federal license revenue and a credible reference point as the Company pursues additional federal opportunities.

About Cyabra

Cyabra is an AI-powered narrative intelligence company that helps national security and defense organizations, government agencies, brands, communications agencies, and global enterprises restore trust and authenticity online by analyzing manipulated content, coordinated behaviors, and inauthentic actors. The platform helps teams understand who is operating, how activity is amplified, and where coordinated activity is shaping perception, translating evidence into clear mitigation steps. By reducing ambiguity and misdirected response, Cyabra enables proportionate, evidence-led action when clarity matters most.
For more information, visit www.cyabra.com.

Contact:

Investors: ir@cyabra.com
Media: pr@cyabra.com

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that are not historical statements of fact and statements regarding Cyabra’s intent, belief, or expectations, including, but not limited to, statements regarding Cyabra’s future results of operations and financial position, planned products and services, business strategy and plans, market size and growth opportunities, competitive position and market trends. Some of these forward-looking statements can be identified by the use of forward-looking words, including “may,” “should,” “expect,” “intend,” “will,” “estimate,” “anticipate,” “believe,” “predict,” “plan,” “targets,” “projects,” “could,” “would,” “continue,” “forecast” or the negatives of these terms or variations of them or similar expressions. For example, the Company is using forward-looking statements in this press release when it discusses the IDIQ contract, the potential issuance of task orders under the contract, the anticipated use of Cyabra’s image and video analysis capabilities by FBI divisions and field offices, anticipated demand for such capabilities, the potential for recurring federal license revenue, and Cyabra’s federal expansion strategy. These statements relate to future events and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include, among others, that the IDIQ contract does not guarantee that Cyabra will receive task orders of any material value; Cyabra’s ability to compete successfully for task orders against other awardees; Cyabra’s ability to satisfy government security and personnel requirements before providing access to FBI users; the Government’s right to suspend or remove Cyabra from the contract following security reviews; the availability of government funding and changes in government procurement priorities; and those set forth in Cyabra’s filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. Cyabra undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.